RESEARCH

Intra-articular injection of monoiodoacetate induces diverse hip osteoarthritis in rats, depending on its dose

Satoshi Yoh1, Yuya Kawarai1*, Shigeo Hagiwara1, Sumihisa Orita1, Junichi Nakamura1, Shuichi Miyamoto2, Takane Suzuki3, Tsutomu Akazawa4, Yuki Shiko5, Yohei Kawasaki5 and Seiji Ohtori1

Abstract
Background: Monoiodoacetate (MIA)-induced arthritis models are used widely in osteoarthritis (OA) research to develop effective conservative treatments for hip OA, as an alternative to joint replacement surgery. In joint OA models, such as the MIA-induced knee OA model, various doses of MIA are utilized, depending on the purpose of the research. So far, only 2 mg of MIA has been used for MIA-induced hip OA research. We hypothesized that the amount of MIA should be adjusted according to the osteoarthritis model under investigation. We performed radiographic and histological evaluations in rats for hip OA models induced by different doses of MIA.

Methods: One hundred and eighty right hips of six-week-old, male Sprague–Dawley rats (n = 30 rats per group) were treated with either a single intra-articular injection of various doses of MIA (0.25, 0.5, 1.0, 2.0, and 4.0 mg) dissolved in 25 μl of sterile saline (MIA group), or with 25 μl of sterile saline alone (Sham group). Radiographic and histological evaluations of the hip joint were performed at one, two, four, eight, and 12 weeks after administration (n = 6 rats per group per time point).

Results: OA changes progressed from 1 week after administration in the 1.0-mg, 2.0-mg, and 4.0-mg MIA groups. The degree of OA changes increased as the dose of MIA increased. The 0.25-mg and 0.5-mg MIA groups presented fewer OA changes than the 2.0-mg and 4.0-mg MIA groups during the entire study period (up to 12 weeks). The administration of 0.25 mg and 0.5 mg of MIA-induced both radiographic and histological OA changes in a time-dependent manner, whereas more than 2 mg of MIA provoked end-stage OA at 8 weeks after injection. Absolute, dose-dependent histopathological OA changes were observed 4 weeks after MIA administration.

Conclusions: Intra-articular MIA injection to the hip joints of rats induced diverse OA changes dose-dependently. Research for developing novel conservative treatments for hip OA and intractable pain should consider the pathological condition when determining the dose of MIA to be employed.

Keywords: Monoiodoacetate (MIA), Hip OA, Hip pain, Animal model

Background
Osteoarthritis (OA) is a major musculoskeletal disorder that affects at least half of the elderly population [1]. Hip and knee OA is rank globally as a significant cause of disorders [2]. Wage losses due to OA amount to US$65 billion; direct medical costs exceed US$100 billion [3]. It is estimated that more than 24 million
people worldwide suffer from symptomatic and activity-restricting hip OA [4, 5]. Patients with hip OA who visit clinics usually complain of hip pain rather than dysfunction (such as limited range of motion or contracture). However, the pain mechanism in osteoarthritis is not yet completely understood. Previous reports have attributed pain to avascular necrosis of the femoral head and hip. OA appears not only in the inguinal region but also in various other locations, such as the anterior thigh and buttocks, making diagnosis difficult [6, 7]. It is important to realize that pain in hip OA is not only derived from bones and cartilages but also from soft tissues, such as the acetabular labrum [8]. In clinical practice, most patients whose hip pain is refractory to symptomatic treatments (such as non-steroidal anti-inflammatory drugs and rehabilitation) usually require total hip arthroplasty (THA). Increasing medical costs due to increasing THAs is also a health economics problem. Since most patients with OA are elderly and often have multiple comorbidities [3], a certain percentage of patients cannot undergo surgery. Therefore, from the viewpoint of both health economics and patient care, we need to develop disease-specific treatments for hip OA.

A few hip OA models have been proposed for the development of new therapeutic agents for hip pain [8, 9]. The MIA intra-articular injection model is commonly utilized for research on OA and OA related pain. Intra-articular injection of 2 mg of MIA into the hip joint induced end-stage hip OA and increased the expression of calcitonin gene-related peptide, an inflammatory neuropeptide in dorsal-root ganglia. It activated transcription factor-3, a selective marker of cell damage following nerve injury [10]. The expression of microglia in the spinal cord also increased in this OA model. The systematic administration of serotonin and norepinephrine reuptake inhibitor attenuated hip pain via descending pain modulatory system, which suggested that end-stage OA is associated with both inflammatory and neuropathic pain [11]. On the other hand, intra-articular administration of 2 mg of MIA provoked relatively strong joint instability, which was different from the gradual OA changes seen in clinical practice. In the MIA-induced knee OA model, it has been reported that the degree of OA varies depending on dose and time after MIA administration [12]. There are no reports describing how osteoarthritic changes of the hip joint proceed depending on the dose of MIA and time course. We hypothesized that the amount of MIA should be adjusted according to what kind of osteoarthritis model is required. We created MIA-induced hip OA models induced by different MIA doses, then evaluated radiographic and histological findings at multiple time points.

Methods

All research protocols in this study were reviewed and approved by the Chiba University Institutional Animal Care and Use Committee and were performed in compliance with the ARRIVE guidelines.

Intra-articular injection of MIA

One hundred eighty male Sprague–Dawley rats (CLEA, Tokyo, Japan), weighing 250–300 g, were housed in a semi-barrier system with a controlled environment (12 h/12 h light/dark cycle; temperature, 21°C–23°C; humidity: 45–65%). Animals were given free access to food and water on arrival. All animals were fed a diet of standard rodent chow (CRF-1; Oriental Yeast, Tokyo, Japan). On the basis of methods previously published [13], all animals were anesthetized using an intraperitoneal injection of 0.3 mg/kg of medetomidine, 4.0 mg/kg of midazolam, and 5.0 mg/kg of butorphanol. All animals were treated aseptically throughout the experiments. Using a 27-gage needle, various concentrations of MIA (Sigma-Aldrich, St. Louis, MO, USA), or sterile saline, were injected into the right hip joints using a posterior approach [9, 14].

Five groups of rats (n = 30 per group) were treated with a single intra-articular injections into the hip joint of various doses of MIA (0.25, 0.5, 1.0, 2.0, and 4.0 mg) dissolved in 25 μl of sterile saline (MIA groups). Thirty rats were injected with 25 μl of sterile saline only (Sham group). The injected agent was confirmed to be restricted to the joint cavity. The animals were examined radiologically and histologically at one, two, four, eight, and 12 weeks after administration (n = 6 rats per group per time point). The rats were euthanized using 3 g of potassium chloride dissolved in 50 ml of sterile saline, administered intravenously (2–4 ml) to anesthetized rats.

X-ray imaging and tissue preparation of the hip joint

Tissue preparations and X-ray imaging of the hip joint were performed as previously described by Miyamoto et al. [9]. After intraperitoneal anesthesia, the rats were laid in the supine position with 0° of hip flexion, abduction, and internal and external rotation. Anteroposterior bilateral X-rays of the hips were taken using the In-Vivo Xtreme imaging system (Bruker, Billerica, MA, USA). Lateral images were taken at 45° of flexion and abduction and at 0° of internal and external rotation. Radiographic assessments were classified using the Kellgren and Lawrence (KL) system [15] as grade 0 (none: no radiographic features of OA), grade 1 (doubtful: doubtful joint space narrowing [JSN] and possible osteophyte), grade 2 (minimal: the presence of definite osteophytes and possible JSN), grade 3 (moderate: multiple osteophytes, definite JSN, sclerosis,
possible bony deformity), and grade 4 (severe: large osteophytes, marked JSN, severe sclerosis and definite bony deformity).

For histological evaluation, the rats were intraperitoneally anesthetized, as described above, and perfused transcardially with 0.9% saline, followed by 500 ml of 4% paraformaldehyde in phosphate buffer fixative (0.1 M, pH 7.4). The soft tissues around the right hip joint (cartilage, synovium, and capsule) were resected. The resected limbs were cut at the mid-femur level and at the center of the femoral head, then immersed in 10% neutral buffered formalin for 3 days. The specimens were continuously demineralized in reagent K-CX (Falma, Tokyo, Japan) for 30 h and in 5% sodium sulfate for 16 h, then paraffin-embedded for coronal sectioning. The samples were serially sectioned in steps of 8-μm and stained using hematoxylin and eosin, Safranin O, and Toluidine Blue. Osteoarthritic changes were evaluated using the Osteoarthritis Research Society International (OARSI) histopathology score [16]. For each joint, we scored ten slices centered on the maximum diameter of the femoral head. Each sample was assessed by the depth (grading) and width (staging) of the osteoarthritic changes. The final score was obtained by multiplying the depth and width.

Statistical analysis
Because grades and OARSI scores were measured in different rats at each time point, we performed two-way analysis of variance (ANOVA). We compared the data between groups at each time point and between time points within each group. Pairwise differences of least-squared means were calculated. The Tukey–Kramer method was used to adjust p-values. A p-value of < 0.05 was considered statistically significant. Statistical analyses were performed using SAS statistical software (version 9.4; SAS Institute, Cary, NC, USA).

Results
X-ray findings
OA changes progressed from 1 week after administration in the 1.0-mg, 2.0-mg and 4.0-mg MIA groups. The degree of OA changes increased as the dose of MIA increased (Fig. 1a). At each time point, the higher the dose of MIA, the stronger the degree of change in the joint (Fig. 1a–e). At 8 weeks after MIA injection, the KL classification grades were nearly equal to 4 in the groups receiving 2 mg or more of MIA (Fig. 1d). At 12 weeks, the KL classification grades reached 4 in the groups receiving more than 1 mg of MIA (Fig. 1e). At the end of the 12th week, progressive to end-stage hip OA changes were observed, except in the Sham and 0.25-mg MIA groups (Fig. 1e, Fig. 2a–r). At 4 weeks after administration, completely dose-dependent OA changes were found (Fig. 1c).

For hips injected with the same dose of MIA, KL classification grades increased in a time-dependent manner in all groups (Fig. 3a–e). At 12-weeks after administration, the 0.25-mg MIA group displayed slight OA (Fig. 3a), the 0.5-mg and 1.0-mg MIA groups presented mild to severe OA (Fig. 3b and c). In the 2-mg and 4-mg MIA groups, the KL classification grades reached a plateau at 8 weeks after administration (Fig. 3d and e).

Histopathological findings
At 1 week after MIA administration, the OARSI scores of the 2.0-mg and 4.0-mg MIA groups were significantly higher than those of the 0.25-mg and 0.5 mg MIA groups (Fig. 4a). They were also higher than those of the 0.25-mg MIA group at 2 weeks after administration (Fig. 4b). At 4 weeks after administration, completely dose-dependent OA changes were observed (Fig. 4c). At eight and 12 weeks after administration, more than 1.0 mg of MIA provoked complete OA changes (Fig. 4d and e, Fig. 2g–r). In rats injected with the same doses of MIA, increases in OARSI scores occurred in a time-dependent manner (Fig. 5a and b). The OARSI scores reached a maximum at 8 weeks after MIA injection in the 1.0-mg and 2.0-mg MIA groups, and at 4 weeks after injection in the 4.0-mg MIA group (Fig. 5c–e).

Discussion
Ours is the first study to investigate radiographic and histological changes after intra-articular injection of various concentrations of MIA to hip joints. Overall, radiographic findings were consistent with histologic findings. OA changes progressed from 1 week after administration in the 1.0-mg, 2.0-mg, and 4.0-mg MIA groups. The degree of OA changes increased as the dose of MIA increased. The 0.25-mg and 0.5-mg MIA groups presented fewer OA changes than the 2.0-mg and 4.0-mg MIA groups over the entire study period of 12 weeks. Interestingly, explicit, dose-dependent, histopathological OA changes were observed 4 weeks after administration. OA progression was noted over time in the 0.25-mg and 0.5-mg MIA groups. More than 2 mg of MIA administration provoked end-stage OA at 8 weeks after MIA injection.

Our radiographic findings were consistent with our histological findings. In a previous study of MIA-induced hip OA, rats injected with 2.0 mg of MIA were radiographically shown to have severe OA 28 days after induction. The histological OARSI scores were 22.7. Thus, the radiographic and histological outcomes were similar [11]. Our results are consistent with these. Another study of MIA-induced hip OA reported that injection of 2 mg of MIA to the hip joints provoked time-dependent OA changes, both radiographic and histologic [9].

Yoh et al. BMC Musculoskeletal Disorders (2022) 23:494
that study, the KL classification grades were 2, 3, and 4, respectively, on days 14, 28, and 56 after MIA administration. The Mankin scores (a histopathological classification of OA severity, ranging from 0 to 14) were 5.0, 8.5, and 12.7, respectively, on days 14, 28, and 56 after MIA injection. Thus, radiographic outcomes were consistent with histological outcomes. This is also consistent with our findings.

OA changes progressed after 1 week of treatment in the 1.0-mg, 2.0-mg, and 4.0-mg MIA groups. The degree of OA changes increased as the MIA dose increased. To the best of our knowledge, no previous report has
clarified dose-dependent OA change after MIA injection to the hip joints. In MIA-induced knee OA models, it has been reported that histological OA changes are induced in a dose-dependent manner [12]. MIA causes a local acute inflammation, followed by the degeneration of cartilage [17, 18]. Kawarai et al. reported that the concentrations of tumor necrosis factor-α (from the synovium of rats injected with 2.0 mg of MIA to the hip joints) significantly increased from Day 7 after induction [14]. A recent study in a MIA-induced knee OA model, using 1.0 mg, 2.0 mg, and 3.0 mg of MIA, explored the levels of chemokines (a family of cytokines that play a crucial role in inflammation and immunity) [19]. The protein levels of chemokine (C-C motif) ligand 2 (CCL2) and chemokine (C-X-C motif) ligand 1 (CXCL1) were increased in synovial fluid from Day 2 after MIA injection into the knee joint. This was more apparent in the 3.0-mg MIA group, compared with the 1.0-mg MIA group [20]. OA progression is associated with inflammation [21]. Thus, it is reasonable that OA changes were observed after 1 week of treatment in the 1.0-mg, 2.0-mg, and 4.0-mg MIA groups, and that the degree of OA changes increased as the MIA dose increased. From the first to the 12th week after administration, the 0.25-mg and 0.5-mg MIA groups displayed fewer OA changes, both radiographic and pathologic, than the 2.0-mg and 4.0-mg MIA groups. OA progression over time was noted in the 0.25-mg and 0.5-mg MIA groups. More than 2 mg of MIA administration provoked end-stage OA at 8 weeks after injection. No previous reports have used a hip OA model to evaluate changes over time in groups treated with different MIA concentrations. In the MIA-induced knee OA model, Udo et al. clarified dose- and time-dependence in MIA-induced OA in rats. MIA concentrations of 0.1 mg, 0.2 mg, and 0.5 mg induced macroscopic cartilage loss in a concentration-dependent manner, which progressed over time from two to 8 weeks after administration [12]. Janusz et al. injected various doses (0.1, 0.25, 0.5, and 1.0 mg) of MIA into the knee joint and performed the histological assessment 3 weeks after induction. Mild cartilage damage was observed at the low dose of 0.1 mg of MIA, whereas severe damage was observed at the high dose of 1 mg. Cartilage damage had proceeded for 3 weeks at the dose of 0.25 mg of MIA [22]. Another study revealed that the administration of 1.0 mg of MIA into the knee joint provoked time-dependent OA. Focal fragmentation and collapse of bony trabeculae with fibrosis and increased osteoclastic activity were observed by 28 days [23]. Guingamp et al. performed functional and histological evaluations at 2 weeks and 4 weeks after administering MIA at high doses (0.3 mg, 3.0 mg) and low doses (0.01 mg, 0.03 mg, and 0.1 mg) [24]. They reported that...
locomotor activity decreased and tissue degeneration increased in high-dose groups, compared with low-dose groups. Fonsi et al. described that the low dose of less than 0.3 mg of MIA injection into the rat knee joint did not attain an appreciable impairment level within 7 days after injection, whereas more than 2 mg of MIA administration led to severe irreversible damage within 14 days [25]. Similarly, in the current study on the hip joint, the 0.25-MIA group did not display any histological OA change. In a rat knee joint model, Ferreira et al. showed that nerve injury markers ATF-3 and NPY (in nerve roots) increased in a dose-dependent manner after administration of MIA at different concentrations (0.3 mg–2 mg) [26]. Kanno et al. compared the literature on histopathological evaluation at 8 weeks after MIA administration to the hip joint. They reported that, in rats with hip OA induced by 0.5 mg of MIA, OARSI scores were approximately 10 at 4
weeks after induction [27]. By contrast, another study reported that OARSI scores were almost at maximum 4 weeks after administration of 2 mg of MIA into the hip joint [11]. These results validate our findings, i.e., more than 2 mg of MIA provoked end-stage OA at 8 weeks after injection. An interesting result of our study is that completely dose-dependent histopathological OA changes were observed 4 weeks after MIA administration. This provides scientists with evidence regarding when to evaluate results for comparison between different concentrations of MIA.

**Clinical relevance**
This is the first research to examine histologic and radiographic changes in hip OA over time after administration of different concentrations of MIA. A previous study
investigated OA changes in hip joints over time after administration of a single concentration of 2 mg MIA [9]. Our study had a longer observation period (12 weeks), which allowed us to explore the fundamental pathology of OA in clinical practice, characterized by the disruption of chondrocyte homeostasis (cracking and erosion), synovitis, exposure of subchondral bone, and osteophyte formation. By applying the results of this study, it is possible
to reproduce various types of OA. For example, a low concentration of MIA (<0.5 mg) should be used to reproduce mild OA; a high concentration of MIA (>2.0 mg) should be used to replicate vigorous deformities, such as pyogenic arthritis, rapidly destructive coxarthrosis, and destruction of the femoral head via rheumatoid arthritis. Moreover, our findings could be useful for elucidating the complex mechanism of pain in OA patients. Research has increasingly emphasized the role of central sensitization in OA, in addition to peripheral sensitization [28–31]. We believe that such research could contribute to elucidation of the mechanism of intractable pain, which significantly impairs the quality of life of OA patients. This may lead eventually to the development of novel treatments for refractory OA pain.

Conclusion
Intra-articular injection of MIA to the hip joints of rats induced diverse OA changes dose-dependently. For research to develop novel conservative treatments for hip OA and intractable hip pain, it is necessary to employ a suitable dose of MIA, according to the pathological condition under investigation.

Acknowledgements
We acknowledge Dr. Yoshinori Nakata’s donation of the in vivo imager (Xtreme) to our university.

Authors’ contributions
S Yoh and Y Kawarai contributed to the original idea, literature review, data collection, statistical analysis, data interpretation, manuscript writing, preparation of figures, revision, and approval of final work. S Orita, T Suzuki, T Akazawa, S Hagiwara, and J Nakamura contributed to the original idea, data interpretation, manuscript revision. S Miyamoto participated in the design of the study and helped to create this study model. Y Shiko and Y Kawasaki contributed to a literature review and data interpretation. S Ohtori contributed to data interpretation and approval of final work. All authors have read and approved the final submitted manuscript.

Funding
This work was supported by a JSPS KAKENHI grant (19K18487) and Nakatomi Foundation.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
We confirm that the study was carried out in compliance with the ARRIVE guidelines. All procedures performed in studies involving experimental animals were in strict accordance with the institutional guidelines for laboratory animal treatment and care and were approved by the Chiba University Institutional Animal Care and Use Committee.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba City, Chiba 260-8677, Japan.
2. Department of Orthopaedic Surgery, Matsudo City General Hospital, 993-1 Sendarai, Matsudo City, Chiba 272-296, Japan.
3. Department of Bioenvironmental Medicine, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba City, Chiba 260-8677, Japan.
4. Department of Orthopaedic Surgery, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan.
5. Biostatistics Section, Clinical Research Center Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba City, Chiba 260-8677, Japan.

Received: 21 December 2021 Accepted: 17 May 2022
Published online: 25 May 2022

References
1. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323–30.
2. Sharma L, Kapoor D, Issa S. Epidemiology of osteoarthritis: an update. Curr Opin Rheumatol. 2006;18(2):147–56.
3. Hawker GA. Osteoarthritis is a serious disease. Clin Exp Rheumatol. 2019;37 Suppl 120S3:6–11.
4. Global Burden of Disease Study C. Global, regional, and national incidence, prevalence, and years lived with disability in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;386(9995):743–800.
5. Jordan JM, Helmick CG, Renner JB, Luta G, Dragomir AD, Woodard J, et al. Prevalence of hip symptoms and radiographic and symptomatic hip osteoarthritis in African Americans and Caucasians: the Johnston County osteoarthritis project. J Rheumatol. 2009;36(4):809–15.
6. Nakamura J, Konno K, Orita S, Hagiwara S, Shigemura T, Nakajima T, et al. Distribution of hip pain in patients with idiopathic osteonecrosis of the femoral head. Mod Rheumatol. 2017;27(3):503–7.
7. Nakamura J, Oinuma K, Ohtori S, Watanabe A, Shigemura T, Sasho T, et al. Distribution of hip pain in osteoarthritis patients secondary to developmental dysplasia of the hip. Mod Rheumatol. 2013;23(1):119–24.
8. Omae T, Nakamura J, Ohtori S, Orita S, Yamauchi K, Miyamoto S, et al. A novel rat model of hip pain by intra-articular injection of nerve growth factor-characteristics of sensory innervation and inflammatory arthritis. Mod Rheumatol. 2015;25(6):931–6.
9. Miyamoto S, Nakamura J, Ohtori S, Orita S, Omae T, Nakajima T, et al. Intra-articular injection of mono-iodoacetate induces osteoarthritis of the hip in rats. BMC Musculoskeletal Disord. 2016;17:132.
10. Miyamoto S, Nakamura J, Ohtori S, Orita S, Nakajima T, Omae T, et al. Pain-related behavior and the characteristics of dorso-plantar ganglia in a rat model of hip osteoarthritis induced by mono-iodoacetate. J Orthop Res. 2017;35(7):1424–30.
11. Kawarai Y, Orita S, Nakamura J, Miyamoto S, Suzuki M, Inage K, et al. Analgesic effect of duloxetine on an animal model of monosodium iodoacetate-induced hip osteoarthritis. J Orthop Res. 2020;38(2):422–30.
12. Udo M, Muneta T, Tsuchi K, Ozeki H, Nakagawa Y, Ohara T, et al. Monosodium iodoacetate acid induces arthritis and synovitis in rats in a dose- and time-dependent manner: proposed model-specific scoring systems. Osteoarthr Cartil. 2016;24(7):1284–91.
13. Kawai Y, Nakamura J, Miyamoto S, Suzuki M, Inage K, et al. Distribution of hip pain in osteoarthritis patients secondary to developmental dysplasia of the hip. Mod Rheumatol. 2013;23(1):119–24.
14. Kawarai Y, Orita S, Nakamura J, Miyamoto S, Suzuki M, Inage K, et al. Changes in proinflammatory cytokines, neuropeptides, and microglia in an animal model of monosodium iodoacetate-induced hip osteoarthritis. J Orthop Res. 2018;36(11):2978–86.
15. Kellogg JH, Lawrence JS. Radiological assessment of osteo-arthritis. Ann Rheum Dis. 1957;16(4):494–502.
16. Pritzker KP, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA, et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthr Cartil. 2006;14(1):13–29.
17. Ivanavicius SP, Ball AD, Heapy CG, Westwood RF, Murray F, Read SJ. Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: increased expression of ATF-3 and pharmacological characterisation. Pain. 2007;128(3):272–82.
18. Marker CL, Pomorici JD. The monosodium iodoacetate model of osteoarthritis pain in the rat. Methods Mol Biol. 2012;851:239–48.
19. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659–702.
20. Bryk M, Chvastek J, Mlóst J, Kostrzewa M, Starowicz K. Sodium Monosodium iodoacetate dose-dependent changes in matrix metalloproteinases and inflammatory components as prognostic factors for the progression of osteoarthritis. Front Pharmacol. 2021;12:643605.
21. Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol. 2011;23(5):471–8.
22. Janusz MJ, Hookfin EB, Heitmeyer SA, Woensner JF, Freemont AJ, Hoyland JA, et al. Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis Cartilage. 2001;9(8):751–60.
23. Guzman RE, Evans MG, Bove S, Morenko B, Kilgore K. Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. Toxicol Pathol. 2003;31(6):619–24.
24. Guingamp C, Geggout-Pottie P, Philippe L, Terlain B, Netter P, Gillet P. Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum. 1997;40(9):1670–9.
25. Fonsi M, El Amrani AJ, Gervais F, Vincent P. Intra-articular hyaluronic acid and chondroitin sulfate: pharmacokinetic investigation in osteoarthritic rat models. Curr Ther Res Clin Exp. 2019;92:100573.
26. Ferreira-Gomes J, Adaes S, Sousa RM, Mendonca M, Castro-Lopes JM. Dose-dependent expression of neuronal injury markers during experimental osteoarthritis induced by monoiiodoacetate in the rat. Mol Pain. 2012;8:50.
27. Kanno K, Suzuki-Narita M, Kawarai Y, Hagiwara S, Yoh S, Nakamura J, Orita S, Image K, Suzuki T, Ōhtori S. Analgesic effects and arthritic changes following tramadol administration in a rat hip osteoarthritis model. J Orthop Res. 2021. https://doi.org/10.1002/jor.25208. Epub ahead of print.
28. Lluch E, Torres R, Nijs J, Van Oosterwijck J. Evidence for central sensitization in patients with osteoarthritis pain: a systematic literature review. Eur J Pain. 2014;18(10):1367–75.
29. Soni A, Wanigasekera V, Mezue M, Cooper C, Javaid MK, Price AJ, et al. Central sensitization in knee osteoarthritis: relating pre-surgical brainstem neuroimaging and PainDETECT-based patient stratification to arthroplasty outcome. Arthritis Rheumatol. 2019;71(4):550–60.
30. Miyagi M, Ishikawa T, Kamoda H, Suzuki M, Inoue G, Sakuma Y, et al. Efficacy of nerve growth factor antibody in a knee osteoarthritis pain model in mice. BMC Musculoskelet Disord. 2017;18(1):428.
31. Orita S, Ishikawa T, Miyagi M, Ochiai N, Inoue G, Eguchi Y, et al. Pain-related sensory innervation in monoiiodoacetate-induced osteoarthritis in rat knees that gradually develops neuronal injury in addition to inflammatory pain. BMC Musculoskelet Disord. 2011;12:134.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.